Filamon sees itself as a drug discoverer and drug developer for major pharma.
Filamon is a public, clinical stage, Australian biotechnology company focused on the development of novel treatments for age-related diseases. Diseases being targeted are inflammation associated with cancer, the eye (wet AMD) and the brain (Alzheimer’s Disease).
A feature of the Filamon drug pipeline is molecules singling out drug targets previously considered to be undruggable because of major safety concerns. Those concerns have led the pharmaceutical industry to a focus on peripheral targets that are safer to inhibit but also less effective as drug targets. Filamon drug candidates are designed to safely drug those targets previously considered off-limits, offering the prospect of major progress in the treatment of major degenerative and inflammatory diseases.
The Company’s Board and Management have decades-long experience in drug and clinical development and corporate management.
Company Details
- Employees
- 7
- Address
- North Sydney, Sydney,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.filamon.com
- Keywords
- prostate cancer, inflammation, Tumour Micro Environment (TME), Wet age-related Macular Degeneration, Alzheimer's disease, VEGF proteins, VCAM-1.
- HQ
- Sydney
Filamon Limited Questions
Filamon Limited's website is http://www.filamon.com
Filamon Limited's LinkedIn profile is https://au.linkedin.com/company/filamon-limited
Filamon Limited has
7 employees.
View email and phone details for 7
employees at Filamon Limited.
Filamon Limited's industry is
Biotechnology Research
Filamon Limited's top competitors are
Nfl Biosciences,
South Harz Potash Ltd,
Aps Biocontrol Ltd.,
Ezzi Vision,
Centre For Population Genomics,
Nested Technologies,
Syntara,
Nyrada Inc. (Asx:nyr),
Ultrace Development Partner,
Kynetyka Technologies Pty Ltd.
Filamon Limited's categories are Biotechnology Research
